AUTHOR=Zhong Xiongdong , Yu Xianchang , Chang Hao 

TITLE=Exploration of a Novel Prognostic Nomogram and Diagnostic Biomarkers Based on the Activity Variations of Hallmark Gene Sets in Hepatocellular Carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.830362

DOI=10.3389/fonc.2022.830362

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>The initiation and progression of tumors were due to variations of gene sets rather than individual genes. This study aimed to identify novel biomarkers based on gene set variation analysis (GSVA) in hepatocellular carcinoma.</p></sec><sec><title>Methods</title><p>The activities of 50 hallmark pathways were scored in three microarray datasets with paired samples with GSVA, and differential analysis was performed with the limma R package. Unsupervised clustering was conducted to determine subtypes with the ConsensusClusterPlus R package in the TCGA-LIHC (<italic>n</italic> = 329) and LIRI-JP (<italic>n</italic> = 232) cohorts. Differentially expressed genes among subtypes were identified as initial variables. Then, we used TCGA-LIHC as the training set and LIRI-JP as the validation set. A six-gene model calculating the risk scores of patients was integrated with the least absolute shrinkage and selection operator (LASSO) and stepwise regression analyses. Kaplan–Meier (KM) and receiver operating characteristic (ROC) curves were performed to assess predictive performances. Multivariate Cox regression analyses were implemented to select independent prognostic factors, and a prognostic nomogram was integrated. Moreover, the diagnostic values of six genes were explored with the ROC curves and immunohistochemistry.</p></sec><sec><title>Results</title><p>Patients could be separated into two subtypes with different prognoses in both cohorts based on the identified differential hallmark pathways. Six prognostic genes (<italic>ASF1A</italic>, <italic>CENPA</italic>, <italic>LDHA</italic>, <italic>PSMB2</italic>, <italic>SRPRB</italic>, <italic>UCK2</italic>) were included in the risk score signature, which was demonstrated to be an independent prognostic factor. A nomogram including 540 patients was further integrated and well-calibrated. ROC analyses in the five cohorts and immunohistochemistry experiments in solid tissues indicated that <italic>CENPA</italic> and <italic>UCK2</italic> exhibited high and robust diagnostic values.</p></sec><sec><title>Conclusions</title><p>Our study explored a promising prognostic nomogram and diagnostic biomarkers in hepatocellular carcinoma.</p></sec>